Disease relevance of Sterinor

• In patients with chronic obstructive airway disease, the elimination half-lives of tetroxoprim (TXP) and sulfadiazine (SDZ) were found to be 8.6-9.0 h and 7.9-8.5 h, respectively, after administration of a single dose [1].

High impact information on Sterinor

• The bacterial and avian QSAR equations can be used to calculate selectivity indices for trimethoprim, tetroxoprim, and two other specially designed 2,4-diamino-5-(substituted-benzyl)pyrimidines [2].
• Biotransformation of tetroxoprim in man [3].
• A comparative clinical trial of tetroxoprim/sulphadiazine and ampicillin in the treatment of purulent bronchial infections [4].
• Two enantiotropic polymorphs of a tetroxoprim (TXP)-sulfametrole (SMTR) 1:1 molecular complex monohydrate and two isostructural TXP-SMTR 1:1 molecular complex solvates with methanol and ethanol were grown and studied by X-ray diffraction and thermal methods (thermogravimetric analysis and differential scanning calorimetry) [5].
• The paper describes a comparative bioavailability study on two tablet formulations containing 100 mg of tetroxoprim and 250 mg of sulphadiazine [6].

Biological context of Sterinor

• Tetroxoprim embonate, an insoluble salt very useful for obtaining a suspension with good palatability, shows a bioavailability not statistically different from that of tetroxoprim base [7].
• The pharmacokinetics of tetroxoprim in the dog [8].

Anatomical context of Sterinor

• Effects of tetroxoprim and sulfadiazine on T lymphocyte proliferation and gamma-interferon production [9].

Analytical, diagnostic and therapeutic context of Sterinor

• Two HPLC methods for determination of tetroxoprim and sulphadiazine in pharmaceutical dosage forms and in biological fluid are reported [7].
• Quantitative determination of tetroxoprim and sulphadiazine in serum and urine was performed using reversed phase high performance liquid chromatography [10].

References